SCHEMBL1857665

SCHEMBL1857665

ICC1CCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1863409 1.00
SCHEMBL11908604 1.00
SCHEMBL1866108 0.92
SCHEMBL3084083 0.85
SCHEMBL25241565 0.85
SCHEMBL15074246 0.81
SCHEMBL2617312 0.81
SCHEMBL22142957 0.81
SCHEMBL153331 0.78
SCHEMBL2394128 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101311176-A Isoquinoline compounds, preparation method and use thereof SHANGHAI INST MATERIA MEDICA (CN) 2008-11-26 CN claimed
WO-2025090284-A1 ELECTROLYTE COMPRISING SOLVENT WITH NON-FLUORINE HALOGEN SUBSTITUTE AND BATTERIES COMPRISING SAME FACTORIAL INC. (US) 2025-05-01 WO disclosed
CN-118373808-A Substituted pyrimidine or pyridine amine derivatives, compositions thereof and pharmaceutical use thereof 上海海雁医药科技有限公司 2024-07-23 CN disclosed
CN-113748110-B Substituted pyrimidine or pyridine amine derivatives, compositions thereof and pharmaceutical use thereof 上海海雁医药科技有限公司 2024-05-14 CN disclosed
US-11820162-B2 Pretreatment liquid, ink set, base material for image recording, method of producing base material for image recording, image recording material, and image recording method FUJIFILM CORPORATION (JP) 2023-11-21 US disclosed
US-20230365561-A1 BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) 2023-11-16 US disclosed
WO-2023215378-A1 METHODS OF TREATING FIBROSIS ATHIRA PHARMA, INC. (US) 2023-11-09 WO disclosed
US-20230320981-A1 SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS INTERVET INC. (US) 2023-10-12 US disclosed
US-20230299360-A1 NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME LG ENERGY SOLUTION, LTD. (KR) 2023-09-21 US disclosed
US-11712416-B2 Solid oral pharmaceutical compositions for isoxazoline compounds INTERVET INC. (US) 2023-08-01 US disclosed
US-7105671-B2 Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2006-09-12 US disclosed
US-20060178429-A1 Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators CORBETT WENDY L 2006-08-10 US disclosed
WO-2006042150-A1 DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2006-04-20 WO disclosed
EP-1501815-A1 SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-02-02 EP disclosed
WO-2003095438-A9 SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2004-12-23 WO disclosed
US-20030225283-A1 Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators CORBETT WENDY LEA (US) 2003-12-04 US disclosed
WO-2003095438-A1 SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2003-11-20 WO disclosed
EP-0415981-A4 RETROVIRAL PROTEASE INHIBITORS 1991-10-09 EP disclosed
EP-0415981-A1 RETROVIRAL PROTEASE INHIBITORS ABBOTT LABORATORIES (US) 1991-03-13 EP disclosed
WO-1989010752-A1 RETROVIRAL PROTEASE INHIBITORS ABBOTT LABORATORIES (US) 1989-11-16 WO disclosed